Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2013

01.08.2013 | original article

Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease

verfasst von: Rodica Anghel, Alexander Bachmann, Meral Bekşac, Univ. Prof. Dr. Thomas Brodowicz, Jindřich Finek, Radko Komadina, Krzysztof Krzemieniecki, Istvan Lang, Jozef Marencak, Roger von Moos, Martin Pecherstorfer, Tamara Rordorf, Damir Vrbanec, Christoph Zielinski

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2013

Einloggen, um Zugang zu erhalten

Summary

Bisphosphonates have been a mainstay in the treatment of cancer-related bone disease and have greatly reduced the risk of skeletal complications. More recently, clinical studies suggested additional benefits of denosumab over zoledronic acid in the prevention of skeletal related events. Similar adverse event profiles have been reported for bisphosphonates and denosumab, with infrequent occurrences of osteonecrosis of the jaw with both agents, higher incidence of renal deterioration with zoledronic acid, and higher incidence of hypocalcaemia with denosumab. Based on current evidence, the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines do not recommend one drug class over the other in patients with metastatic bone disease. Denosumab, however, may present advantages over bisphosphonates in patients suffering from chronic renal insufficiency. Further research and growing clinical experience will refine the evidence based on which decisions in daily clinical practice can be taken.
Literatur
1.
Zurück zum Zitat Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–76.PubMedCrossRef Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–76.PubMedCrossRef
3.
Zurück zum Zitat Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 2010;19(6):755–60.CrossRef Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 2010;19(6):755–60.CrossRef
4.
Zurück zum Zitat Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumours: a randomised, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613–21.PubMedCrossRef Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumours: a randomised, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613–21.PubMedCrossRef
5.
Zurück zum Zitat Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomised, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.PubMedCrossRef Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomised, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.PubMedCrossRef
6.
Zurück zum Zitat Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomised, placebo-controlled trials. Cancer. 2000;88(5):1082–90.PubMedCrossRef Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomised, placebo-controlled trials. Cancer. 2000;88(5):1082–90.PubMedCrossRef
7.
Zurück zum Zitat Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modelling and remodelling. Arch Biochem Biophys. 2008;473(2):139–46.PubMedCrossRef Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modelling and remodelling. Arch Biochem Biophys. 2008;473(2):139–46.PubMedCrossRef
8.
9.
Zurück zum Zitat Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005;5(6):618–25.PubMedCrossRef Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005;5(6):618–25.PubMedCrossRef
10.
Zurück zum Zitat O’Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun. 2000;274(2):281–90.CrossRef O’Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun. 2000;274(2):281–90.CrossRef
11.
Zurück zum Zitat Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000;157(2):435–48.PubMedCrossRef Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000;157(2):435–48.PubMedCrossRef
12.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.PubMedCrossRef Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.PubMedCrossRef
13.
Zurück zum Zitat Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology. 2000;141(12):4768–76.PubMedCrossRef Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology. 2000;141(12):4768–76.PubMedCrossRef
14.
Zurück zum Zitat Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584–93.PubMedCrossRef Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584–93.PubMedCrossRef
15.
Zurück zum Zitat Van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone. 2002;30(1):64–70.PubMedCrossRef Van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone. 2002;30(1):64–70.PubMedCrossRef
16.
Zurück zum Zitat Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Monkkonen J, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int. 2002;70(1):40–7.PubMedCrossRef Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Monkkonen J, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int. 2002;70(1):40–7.PubMedCrossRef
17.
Zurück zum Zitat Coleman R, Abrahamsson P-A, Hadhi P. editors. Handbook of cancer-related bone disease. UK:BioScientifica; 2000. Coleman R, Abrahamsson P-A, Hadhi P. editors. Handbook of cancer-related bone disease. UK:BioScientifica; 2000.
18.
Zurück zum Zitat Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314–21.PubMedCrossRef Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314–21.PubMedCrossRef
19.
Zurück zum Zitat Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735–44.PubMedCrossRef Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735–44.PubMedCrossRef
20.
Zurück zum Zitat Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399–405.PubMedCrossRef Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399–405.PubMedCrossRef
21.
Zurück zum Zitat Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, Boer RH de, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study. J Clin Oncol. 2010;28(35):5132–9.PubMedCrossRef Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, Boer RH de, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study. J Clin Oncol. 2010;28(35):5132–9.PubMedCrossRef
22.
Zurück zum Zitat Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82.PubMedCrossRef Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82.PubMedCrossRef
23.
Zurück zum Zitat Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.PubMedCrossRef Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.PubMedCrossRef
24.
Zurück zum Zitat Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase III, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.PubMedCrossRef Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase III, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.PubMedCrossRef
25.
Zurück zum Zitat Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol. 2007;19(4):315–22.PubMedCrossRef Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol. 2007;19(4):315–22.PubMedCrossRef
26.
Zurück zum Zitat Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Suppor Care Cancer. 2011;19(12):2035–40.CrossRef Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Suppor Care Cancer. 2011;19(12):2035–40.CrossRef
27.
Zurück zum Zitat Guarneri V, Donati S, Nicolini M, Giovannelli S, D’Amico R, Conte PF. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist. 2005;10(10):842–8.PubMedCrossRef Guarneri V, Donati S, Nicolini M, Giovannelli S, D’Amico R, Conte PF. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist. 2005;10(10):842–8.PubMedCrossRef
28.
Zurück zum Zitat Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36–43.PubMedCrossRef Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36–43.PubMedCrossRef
29.
Zurück zum Zitat Moos R von, Caspar CB, Steiner R, Angst R, Inauen R, Schmieding K, et al. Long-term renal safety profile of ibandronate 6 mg infused over 15 min. Onkologie. 2010;33(8–9):447–50. Moos R von, Caspar CB, Steiner R, Angst R, Inauen R, Schmieding K, et al. Long-term renal safety profile of ibandronate 6 mg infused over 15 min. Onkologie. 2010;33(8–9):447–50.
30.
Zurück zum Zitat Body JJ, Diel IJ, Tripathy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl). 2006;15(3):299–302.CrossRef Body JJ, Diel IJ, Tripathy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl). 2006;15(3):299–302.CrossRef
31.
Zurück zum Zitat Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471–9.PubMedCrossRef Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471–9.PubMedCrossRef
32.
Zurück zum Zitat Xgeva (Denosumab) Summary of Product Characteristics. European Medicines Agency [updated 11/09/2012 cited (2012)]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002173/human_med_001463.jsp&mid=WC0b01ac058001d124. Accessed: 17. Sept. 2012. Xgeva (Denosumab) Summary of Product Characteristics. European Medicines Agency [updated 11/09/2012 cited (2012)]. http://​www.​ema.​europa.​eu/​ema/​index.​jsp?​curl=​pages/​medicines/​human/​medicines/​002173/​human_​med_​001463.​jsp&​mid=​WC0b01ac058001d1​24.​ Accessed: 17. Sept. 2012.
33.
Zurück zum Zitat Van Poznak CH, Von Roenn JH, Temin S. American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract. 2011;7(2):117–21.PubMedCrossRef Van Poznak CH, Von Roenn JH, Temin S. American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer. J Oncol Pract. 2011;7(2):117–21.PubMedCrossRef
34.
Zurück zum Zitat Network NCC. NCCN clinical practice guidelines in concology: prostate cancer, version 4.2011. (2011). http://www.nccn.org. Accessed: 20. Feb. 2012. Network NCC. NCCN clinical practice guidelines in concology: prostate cancer, version 4.2011. (2011). http://​www.​nccn.​org.​ Accessed: 20. Feb. 2012.
35.
Zurück zum Zitat Summary of product characteristics. European Medicines Agency. http://www.ema.europa.eu/ema/. Accessed: 18. Sept. 2012. Summary of product characteristics. European Medicines Agency. http://​www.​ema.​europa.​eu/​ema/​.​ Accessed: 18. Sept. 2012.
36.
Zurück zum Zitat Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420–32.PubMedCrossRef Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19(3):420–32.PubMedCrossRef
Metadaten
Titel
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease
verfasst von
Rodica Anghel
Alexander Bachmann
Meral Bekşac
Univ. Prof. Dr. Thomas Brodowicz
Jindřich Finek
Radko Komadina
Krzysztof Krzemieniecki
Istvan Lang
Jozef Marencak
Roger von Moos
Martin Pecherstorfer
Tamara Rordorf
Damir Vrbanec
Christoph Zielinski
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0385-4

Weitere Artikel der Ausgabe 15-16/2013

Wiener klinische Wochenschrift 15-16/2013 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Preisverleihung